Stocks · News reference
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
Achieve Life Sciences presented 52-week data for its cytisinicline program, which is being developed as a treatment for nicotine dependence, at the CHEST 2026 annual meeting.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ACHIEVE LIFE SCIENCES, INC. (ACHV)
Filed: 2026-10-01 AccNo: 0001193125-26-410781 Size: 209 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Achieve Life Sciences Appoints Benjamin Halladay CFO, Effective Oct. 5